Bristol-Myers Squibb
Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMY
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.
BMY Key Statistics
Stock Snapshot
With a market cap of 130.25B, Bristol-Myers Squibb(BMY) trades at $61.75. The stock has a price-to-earnings ratio of 17.92 and currently yields dividends of 4.0%.
As of 2026-02-09, Bristol-Myers Squibb(BMY) stock has fluctuated between $58.92 and $62.04. The current price stands at $61.75, placing the stock +4.8% above today's low and -0.5% off the high.
The Bristol-Myers Squibb(BMY)'s current trading volume is 17.12M, compared to an average daily volume of 14.39M.
In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.
In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.
BMY News
Bristol-Myers Squibb (BMY) has moved back into the spotlight after reporting fourth quarter and full year 2025 results, combining higher profitability, flat ann...
Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Bristol-Myers Squibb, boosting the price target to $68.00. Claim 50% Off TipRank...
Bristol-Myers Squibb Company ((BMY)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fun...
Analyst ratings
60%
of 30 ratingsMore BMY News
Srikripa Devarakonda, an analyst from Truist Financial, maintained the Buy rating on Bristol-Myers Squibb. The associated price target remains the same with $65...
Bristol Myers’ Growth Portfolio surged 16% to $7.4B in Q4 while Legacy Portfolio fell 15% on generic competition. Bristol Myers Squibb (BMY) guided 2026 revenu...
Bristol-Myers Squibb ( (BMY) ) has provided an update. On February 5, 2026, Bristol Myers Squibb reported its fourth-quarter and full-year 2025 financial resul...
(RTTNews) - While reporting financial results for the fourth quarter on Thursday, Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue gro...
Bristol-Myers Squibb (NYSE:BMY) has agreed to acquire Orbital Therapeutics to expand its RNA-based therapies portfolio for cancer and autoimmune diseases. The...
Bristol-Myers Squibb (NYSE:BMY) agreed to acquire Orbital Therapeutics, adding RNA-based therapies for cancer and autoimmune diseases to its pipeline. Lupin la...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.